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00106.2016.—Preeclampsia is a multisystem disease that significantly
contributes to maternal and fetal morbidity and mortality. In this
study, we used a non-biased microarray approach to identify dysregu-
lated genes in maternal whole blood samples which may be associated
with the development of preeclampsia. Whole blood samples were
obtained at 28 wk of gestation from 5 women who later developed
preeclampsia (cases) and 10 matched women with normotensive
pregnancies (controls). Placenta samples were obtained from an in-
dependent cohort of 19 women with preeclampsia matched with 19
women with normotensive pregnancies. We studied gene expression
profiles using Illumina microarray in blood and validated changes in
gene expression in whole blood and placenta tissue by qPCR. We
found a transcriptional profile differentiating cases from controls; 336
genes were significantly dysregulated in blood from women who
developed preeclampsia. Functional annotation of microarray results
indicated that most of the genes found to be dysregulated were
involved in inflammatory pathways. While general trends were pre-
served, only HLA-A was validated in whole blood samples from cases
using qPCR (2.30- 0.9-fold change) whereas in placental tissue
HLA-DRB1 expression was found to be significantly increased in
samples from women with preeclampsia (5.88- 2.24-fold change).
We have identified that HLA-A is upregulated in the circulation of
women who went on to develop preeclampsia. In placenta of women
with preeclampsia we identified that HLA-DRB1 is upregulated. Our
data provide further evidence for involvement of the HLA gene family
in the pathogenesis of preeclampsia.
preeclampsia; gene expression; placenta; microarray
OF ALL PREGNANCIES worldwide, 2–8% are affected by the
severe form of spontaneous pregnancy-induced hypertension:
preeclampsia (29). Preeclampsia is broadly defined by Inter-
national Society for the study of Hypertension in Pregnancy
(ISSHP) criteria as the de novo development of hypertension
after gestational week 20 accompanied by the new onset of one
or more of the following: proteinuria, renal insufficiency, liver
disease, neurological conditions, hematological disturbances,
or fetal growth restriction (35). The disease contributes to
maternal and perinatal morbidity and mortality as well as
conferring increased long-term risk of chronic illnesses (16,
29). There is a need for greater understanding of the underlying
multifactorial development that predates the clinical presenta-
tion of preeclampsia. Furthermore, the only cure for pre-
eclampsia is timely delivery of the placenta as well as the baby;
therefore, the basis of the disease is thought to be dysfunction
of the placenta.
The fundamental changes that occur between a healthy
pregnancy and the development of preeclampsia may be asso-
ciated with changes in gene expression. In particular, examin-
ing large-scale gene expression in the circulation provides an
accessible source that can be informative of disease states.
Previous studies by other groups that have looked at gene
expression in whole blood or peripheral blood monocytes
(PBMCs) from women with preeclampsia have been analyzed
in samples taken at clinical presentation (6, 30, 33) or at
delivery (8, 25) and lacked translation into pregnancy-specific
tissues (6, 8, 25, 30, 33). In our study, we aimed to analyze
gene expression patterns at a time point before clinical presen-
tation of preeclampsia to gain insight into the pathogenic
processes that are involved in the development of the condi-
tion.
MATERIALS AND METHODS
Patients
Whole blood microarray cohort. For the microarray study, whole
blood samples from women recruited between 2007 and 2010 as part
of the prospective “Proteomics in Preeclampsia” (PIP) study were
used. The study protocol has been described elsewhere (5); in brief
4,000 women were recruited across Glasgow at their initial antenatal
hospital appointment. Inclusion criteria were as follows: women with
singleton pregnancies were recruited at gestational week 12–16.
Women with a history of chronic hypertension, diabetes, or renal
disease were not included in the study. Further samples were obtained
from 180 women with two or more risk factors for preeclampsia
[nulliparity, age over 35 yr, body mass index (BMI) 30 kg/m2,
family history of preeclampsia in mother or sister (11)] at gestational
weeks 16 and 28. All women were followed until delivery, when
pregnancy outcomes were obtained from labor ward databases and
hospital case records. From this study, whole blood samples taken at
28 wk gestation were obtained in a subset of women who went on to
develop preeclampsia (n  5) who were matched for age, BMI, and
parity with two normotensive women (controls) per case (total of n 
10); these samples were subject to microarray analysis. None of the
five women who went on to develop preeclampsia were treated with
blood pressure medication at the time of sample collection.
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Placental tissue cohort. Placental biopsies were collected at deliv-
ery from a second cohort, independently from the PIP study, of 38
women, 19 of whom were diagnosed with preeclampsia according to
ISSHP criteria and 19 normotensive subjects matched for age, BMI,
and parity. Women were all nonlaboring and underwent caesarean
section. None of the women had a medical history of cardiovascular
or metabolic disease, and multiparous pregnancies were excluded.
Subject characteristics were recorded at the time of tissue collection,
and delivery details were recorded from patient notes. Within the
subgroup of women who developed preeclampsia: three were treated
with labetalol, one was treated with nifedipine, one was treated with
betamethasone, and one was treated with betamethasone, labetalol,
and nifedipine. Dosage information was not available. The other
patients in the cohort did not receive any treatment. Customized birth
weight centiles were calculated using the Gestation Network Centile
Calculator 5.4 (http://www.gestation.net/birthweight_centiles/centile_
online.htm). All biopsies were full thickness; therefore, they incorpo-
rated both maternal and fetal tissue. Tissue was flash-frozen in liquid
nitrogen and stored at 80°C until analysis.
The PIP Study and the collection of placenta tissue were approved
by the West of Scotland Research Ethics Committee and adhere to the
principles of the Declaration of Helsinki. All participants gave written
informed consent.
RNA Extraction
RNA extraction from whole blood samples (PAXgene blood RNA
tubes, Qiagen) or placental tissues was performed using the miRNeasy
mini kit (Qiagen) according to manufacturer’s instructions. Samples
were processed according to manufacturer’s protocol. Each sample’s
total RNA concentration was determined by Nanodrop (Thermo
Fisher Scientific) and stored at 80°C until use.
Illumina Microarray
RNA was amplified and biotin-labeled by in vitro transcription to
complementary RNA (cRNA) using the Illumina TotalPrep RNA
Amplification Kit (AMIL1791) according to manufacturer’s instruc-
tions with 500 ng RNA input. All incubations were performed using
an MJ Research PTC Gradient Cycler, and cRNA sample quality was
Table 1. Characteristics of women in the microarray study
cohort
Cases
(n  5)
Controls
(n  10) P Value
Age, yr 33.2  1.3 33.8  0.5 NS
BMI, kg/m2 29.9  0.98 29.2  0.95 NS
Smoker, n 0 1 (10%) NS
Nulliparous 4 (80%) 6 (60%) NS
Previous preeclampsia 0 0 NS
Family history (mother or sister)
of preeclampsia 0 0 NS
SBP 28 wk gestation, mmHg 134  3 113  2 0.044
DBP 28 wk gestation, mmHg 86  3 70  1 0.054
Caesarean section, n 1 (20%) 0 NS
Gestation at delivery, wk 38.8  0.6 40.4  0.8 NS
Birth weight, g 3065  120 3358  69 NS
Data are presented as means  SD. Whole blood samples taken at 28 wk of
gestation from 5 women who developed preeclampsia (cases) were matched
for 10 women who went on to have normotensive pregnancies (controls). Both
systolic and diastolic blood pressure were significantly elevated in cases
relative to controls; despite these samples being taken before the onset of labor
or diagnosis of preeclampsia. BMI, body mass index; SBP, systolic blood
pressure; DBP, diastolic blood pressure; NS, not significant.
Fig. 1. Microarray analysis shows differen-
tial gene expression in whole blood samples
taken at 28 wk gestation from women who
went on to develop preeclampsia. Microar-
ray analysis was conducted in whole blood
samples from women who went on to have
a normotensive pregnancy (n  10) and
women who developed preeclampsia. The
microarray data was preprocessed with
GenomeStudio, undergoing background
subtraction and quantile normalization. Data
were monotonically transformed by taking
their logarithm to base 2 after adding a
constant to all values. The constant was
added to ensure that background subtracted
values were all positive and for noise reduc-
tion of very low expression probes. Rank
products implementation in R was used for
significance testing. All P values were cor-
rected for multiple testing using false dis-
covery rate (FDR); a P value of 0.05 was
considered to be significant. Black dots ()
accompanied by gene names represent those
that were taken forward for Ingenuity Path-
way Analysis.
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assessed by Agilent 2100 Bioanalyzer before hybridization onto the
Illumina Human HT microarray chip (Human HT-12 v4.0 Gene
Expression Bead Chip BD-103-0204, Illumina). Samples were loaded
to the chips with 750 ng cRNA input and incubated overnight at 58°C.
The chips were washed in E1BC buffer, stained with streptavidin-
Cy3, and scanned using the Illumina BeadArray Reader. The output
data was visualized using Beadstudio software.
Reverse-Transcriptase Polymerase Chain Reaction
Gene expression reverse-transcriptase polymerase chain reaction
(RT-PCR) was performed using the Taqman Reverse Transcription
Kit (Applied Biosystems) according to manufacturer’s instructions
with 400 ng RNA input. The reaction was run on a Multi Block
System Satellite 0.2 Thermo Cooler (Thermo Fisher Scientific) on the
following settings: 25°C 10 min, 48°C 30 min, 95°C 5 min.
Quantitative PCR
Reactions were set up using the following reagents: Taqman
Universal Mastermix (Applied Biosystems), dH2O, and relevant Taq-
man probe (Applied Biosystems). Gene expression protocol was run
on an ABI PRISM 7900HT PCR system at the following settings:
95°C, 15 min; followed by 40 cycles of 95°C, 15 s; 60°C, 1 min.
Threshold cycle (CT) values were analyzed using the 2(delta delta
Ct) method, with dCt indicating normalization to the housekeeper,
ubiquitin C (UBC).
Statistical Analysis
The microarray data were preprocessed with GenomeStudio, un-
dergoing background subtraction and quantile normalization. Data
were monotonically transformed by taking their logarithm to base 2
after adding a constant to all values. The constant was added to ensure
that background subtracted values were all positive and for noise
reduction of very low expression probes. Rank products implementa-
tion in R was used for significance testing. All P values were corrected
for multiple testing using false discovery rate (2). Several extreme
results had incalculable P values, sitting outside of the simulated null
distribution, and are described as being less than the lowest calculated
value. Quantitative (q)PCR data are represented as means SE and
are displayed on the relative quantification scale. Parameters mea-
sured in patient cohorts, gene expression changes identified from the
microarray and all qRT-PCR data were analyzed using a Student’s
t-test where significance was defined as P  0.05, and data were
analyzed on the delta-CT scale. Pearson correlation was used to
estimate linear relationship between gene expression and birthweight
or placental weight. Fisher’s transformation was used to test the null
hypothesis that population correlation, , equals 0.
RESULTS
Whole Blood Samples Taken at 28 wk Gestation in Women
Who Went on to Develop Preeclampsia Show a Differential
Gene Expression Profile
Whole blood samples collected at 28 wk gestation from
women who went on to develop preeclampsia (n  5) and
women with normotensive pregnancies (n  10) were subject
to gene expression analysis using Illumina microarray. Char-
acteristics of this patient cohort are shown in Table 1. Of the
47,000 probes present on the microarray, 336 genes were found
Fig. 2. Ingenuity Pathway Analysis (IPA) of genes that were significantly differentially expressed in whole blood samples from women who went on to develop
preeclampsia from microarray. A and B: the genes that had the largest fold change from the microarray; either increased or decreased respectively. Biological
pathway search was modified to include direct or indirect relationships where gene involvement had been experimentally validated. Disorders of the immune
system featured multiple times in both network analysis (C) and in association with disease and disorders (D).
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to be significantly differentially regulated in women who went
on to develop preeclampsia, 163 genes were significantly
upregulated, while 173 genes were significantly downregulated
(Fig. 1).
Genes that were significantly differentially regulated be-
tween the two groups were subject to Ingenuity Pathway
Analysis (IPA) to delineate their involvement in biological
pathways of interest. Disorders of the immune system were
among the main hits from IPA analysis (Fig. 2). We chose five
genes, HLA-A, HLA-C, HLA-DRB1, GSTM2, and PRKAR1A,
to take forward for further study on the basis of the highest fold
change and/or biological function determined from IPA and a
literature search (Table 2).
HLA-A was Significantly Upregulated in Whole Blood from
Women Who Went on to Develop Preeclampsia
The genes of interest shown in Table 2 were subject to qPCR
validation in the same whole blood samples that were used for
the microarray (Fig. 3). While general trends in upregulation
and downregulation from the microarray were preserved, only
HLA-A was found to be statistically significantly upregulated in
the qPCR experiment. HLA-C, HLA-DRB1, GSTM2, and
PRKAR1A were not found to validate at this stage. In agree-
ment with the microarray data, HLA-A was upregulated in
women who went on to develop preeclampsia but to a lesser
extent (log2 fold change: 2.30  0.9) than in the microarray
experiment.
HLA-DRB1 is Significantly Upregulated in Placental Tissue
from Women with Preeclampsia
Following the discovery of an altered gene expression pro-
file in the circulation of women who went on to develop
preeclampsia, we then sought to investigate a subset of the
genes of interest in a tissue with pregnancy-specific relevance.
Placental samples were collected at delivery from women with
preeclampsia (n 19) and matched women with normotensive
pregnancies (n  19) (Table 3). The higher HLA-A expression
seen in whole blood from cases was not mirrored in the
placental tissue (Fig. 4A). However, expression of HLA-DRB1
was significantly increased in placental tissue from women
with preeclampsia (fold change: 5.88  2.24) (Fig. 4B). We
found that placental expression of HLA-A (r2  0.19, P 
0.008) and HLA-DRB1 (r2  0.18, P  0.03) was significantly
correlated with birthweight (Fig. 5, A and B). Where placental
weight data were available, HLA-A and HLA-DRB1 were not
associated with a reduced placental weight (Fig. 5, C and D).
DISCUSSION
This microarray study identified a number of novel genes
that were dysregulated in the circulation of women who went
on to develop preeclampsia. Of the 336 genes that were
significantly differentially expressed, we selected five on the
basis of fold change and biological function. One strength of
our study is the translation from whole blood to a relevant
tissue involved in the pathology of preeclampsia. Placental
dysfunction is regarded as the main cause of preeclampsia
symptoms, as delivery of the placenta as well as the baby is the
only effective cure for this disease. While significant changes
in circulating HLA-A were not supported by changes in pla-
cental tissue, another gene of interest identified from the Ta
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microarray, HLA-DRB1, was significantly upregulated in pla-
cental tissue from women with preeclampsia.
The pregnane-X-receptor/retinoid-X-receptor (PXR/RXR
pathway) is involved in the metabolism of xenobiotics through
activation of the cytochrome P450 family of enzymes (34). In
this study, GSTM2 and PRKAR1A were identified to be differ-
entially regulated from the microarray in whole blood from
women with preeclampsia and are an intrinsic part of this
pathway. Impaired liver function can be a clinical feature of
preeclampsia thus these genes were of potential interest, how-
ever, they did not validate at the level of qPCR. The other
targets identified from the microarray, HLA-A, HLA-C, and
HLA-DRB1, are derived from the human major histocompati-
bility complex (MHC) known as the human leukocyte antigen
(HLA) family in humans. The principle function of the MHC/
HLA family is to act in the recognition of “self” through
antigen presentation to induce the relevant response from the T
cell (27). HLA-A and HLA-C encode proteins belonging to
class I MHC. Class I MHC are found on the cell surface of all
nucleated cells in the body where they function to display
cytosolic peptides derived from nonself-proteins. HLA-DRB1
encodes a subunit of an MHC class II receptor. Where class I
receptors are ubiquitously expressed; class II receptors are
generally restricted to antigen presenting cells.
One gene of those selected from the microarray, HLA-A, was
validated with qPCR. There are both technical and biological
reasons for this disparity between microarray and qPCR data.
Technically, despite the use of stringent thresholds, microarray
data can produce a high number of false positives (23). A
larger patient cohort may also have been able to reduce error in
qPCR measurement of gene expression, resulting in more
statistically significant changes. Biologically, preeclampsia is a
heterogeneous disease encompassing a number of underlying
pathologies resulting in distinct clinical outcomes. Early- and
late-onset preeclampsia are the extremes of this continuum
(36), and differences in gene expression in whole blood sam-
ples between the two conditions have been described (6, 8).
Fig. 3. HLA-A is significantly upregulated in whole blood samples at 28 wk gestation from women who went on to develop preeclampsia following quantitative
(q)PCR validation. Mature mRNA expression of genes of interest were measured by qPCR in whole blood samples from women with preeclampsia (PE) at 28
wk (n 5) and women with normotensive pregnancies (control) (n 10). Data was analyzed by Student’s t-test where P 0.05 was considered to be significant
(**P  0.01 vs. control). HLA-A, major histocompatibility complex, class I, A; HLA-C, major histocompatibility complex, class I, C; HLA-DRB1, major
histocompatibility complex, class II, DR beta 1; GSTM2, glutathione S-transferase mu 2; PRKAR1A, protein kinase CAMP-dependent type I regulatory subunit
alpha; UBC, ubiquitin C.
Table 3. Characteristics of the placental tissue cohort
Cases
(n  19)
Controls
(n  19) P Value
Age, yr 29  5.4 30  4.6 NS
BMI, kg/m2 29.5  6.8 29.4  6.7 NS
Smoker, n 4 (21.1%) 5 (26.3%) NS
Nulliparous 11 8 NS
Third trimester SBP, mmHg 148 25 123  19 0.001
Third trimester DBP, mmHg 93 16 73  9.4 0.001
Gestation at delivery, wk 35.9  3.2 39.4  1.5 0.001
Birth weight, g 2463  840 3573  652 0.001
Data are presented as means  SD. Placental samples taken at delivery from
19 women with preeclampsia (cases) were matched for age (29.7 0.7 yr) and
BMI (29.4  6 kg/m2) to 19 women who had normotensive pregnancies
(controls). Women with preeclampsia from this cohort, on average, delivered
before full term. BMI, body mass index; SBP, systolic blood pressure; DBP,
diastolic blood pressure.
197HLA GENE EXPRESSION IN PREECLAMPSIA
Physiol Genomics • doi:10.1152/physiolgenomics.00106.2016 • www.physiolgenomics.org
 by 10.220.32.246 on April 24, 2017
http://physiolgenom
ics.physiology.org/
D
ow
nloaded from
 
One limitation with respect to our study is that the clinical
parameters of the patient cohort from which the blood samples
were collected were more representative of late-onset pre-
eclampsia, whereas the cohort of women who gave placental
samples was more representative of severe, early-onset pre-
eclampsia. The heterogeneity of preeclampsia itself and differ-
ent times of onset across our study cohorts may add a con-
founding factor with respect to gene expression analysis, in-
creasing the range of values, and therefore error, making it
difficult to see clear significant differences.
Fig. 4. HLA-DRB1 is significantly upregu-
lated in placental tissue from women with
preeclampsia. Mature mRNA expression of
genes of interest were measured by qPCR in
placental tissue samples from women with
preeclampsia (PE) (n  19) and women with
normotensive pregnancies (control) (n 19).
Data was analyzed by Student’s t-test where
P  0.05 was considered to be significant
(*P  0.05 vs. control). HLA-A, major his-
tocompatibility complex, class I, A; HLA-
DRB1, major histocompatibility complex,
class II, DR beta 1; GSTM2, glutathione S-
transferase mu 2.
Fig. 5. High HLA-A and HLA-DRB 1 expres-
sion are significantly correlated with a re-
duced birthweight but not placental weight.
Gene expression values (CT) were subject to
Pearson’s correlation and Fisher’s transfor-
mation where birthweight (n  28) or pla-
cental weight values (n 16) were available.
These samples were derived from the placen-
tal cohort. HLA-A (A) CI (0.67 to 0.12)
and HLA-C (B) CI (0.69 to 0.06) gene
expression were significantly correlated with
birthweight but not placental weight (C and
D). A P  0.05 was considered to be signif-
icant. HLA-A, major histocompatibility com-
plex, class I, A; HLA-DRB1, major histocom-
patibility complex, class II, DR beta 1.
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Pregnancy itself is a major immunological adaptation from
implantation to parturition. Mild activation of the immune
system throughout the course of pregnancy and a slight in-
crease toward delivery are indicated by a raised white blood
cell count and proinflammatory cytokines (26). Recent work in
preeclampsia has focused on the role of T cells and adaptive
immunity in preeclampsia; both HLA-A and HLA-DRB1 iden-
tified from this study are involved in the biology of T cells.
While we cannot make any conclusive statements about the
underlying mechanism of the greater HLA gene expression in
women who went on to develop preeclampsia in this study,
further investigation of the interaction between antigen-pre-
senting cells, such as those that express HLA-DRB, and T cells
should be examined. Overall, our findings are in keeping with
a role for T cells and adaptive immunity in the pathology of
preeclampsia.
The main effectors of spiral artery remodeling are the fetally
derived extravillous trophoblasts; failure of the maternal spiral
arteries to remodel is a pathological hallmark of preeclampsia
(3). The extravillous trophoblasts are thought to evade the host
immune system as they invade the uterine wall partly by
expression of a unique combination of MHC class I molecules:
HLA-C, HLA-E, and HLA-G (17, 18, 24). Therefore, the
expression we detected of HLA-A and HLA-DRB1 in the
placenta was most likely to be from maternal not trophoblast
tissue. Certain forms of the HLA genes expressed by the
extravillous trophoblasts have been previously reported in the
literature to have an involvement with preeclampsia. Reduction
in HLA-G, both maternally through functional single nucleo-
tide polymorphisms in the HLA-G gene (14, 19) or reduction in
fetally derived trophoblasts (20), has been related to an in-
creased incidence of preeclampsia. Additionally, certain com-
binations of alleles of the fetal HLA-C gene and maternal killer
immunoglobulin like receptor (KIR) on NK cells have been
shown to have an increased incidence of preeclampsia (13).
However, in this study, differential expression of HLA-C was
not validated with qPCR.
While the HLA genes expressed by the trophoblast have
been subject to much study with respect to their involvement in
preeclampsia, to date, the two genes that we have validated in
this study, HLA-A or HLA-DRB1, have not previously been
associated with the disease. HLA-A and HLA-DRB1 have
however been related to a reduced birthweight (4, 28); we also
observed a significant correlation between HLA-A and HLA-
DRB1 gene expression and reduced birthweight but not pla-
cental weight. Both placental weight (9) and birthweight (21)
have been found to be significantly decreased in women with
preeclampsia. Notably in our cohort, the sample size available
for placental weight was considerably smaller than for birth-
weight, but where data were available for both, the placental
weight and birth weight were significantly correlated (data not
shown).
Other studies using microarray technology have also iden-
tified a distinct profile of gene expression in whole blood (6, 8,
33) or PBMCs (25, 30) from women with preeclampsia. While
neither HLA-A or HLA-DRB1 has been previously reported in
these studies, genes involved in the immune response have
been shown to be differentially expressed in women with
preeclampsia (6, 8, 33). In these studies, changes in immune-
related gene expression were more apparent in women with
severe early-onset preeclampsia. This supports our findings
that women with preeclampsia have a significantly different
gene expression profile in whole blood specifically with respect
to those involved in the function of the immune system. In
conclusion, we and others have shown a distinct transcriptional
profile in whole blood samples from women with preeclamp-
sia. Currently, preeclampsia is a disease of significant burden
on both the mother and fetus without an effective screening
method or treatment. Future work should seek to validate as
many of these novel targets identified from screens such as
ours in larger independent cohorts of patients to assess whether
these are indicators of functional pathology on a molecular
basis.
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